MX2010001571A - Predictive markers for egfr inhibitor treatment. - Google Patents
Predictive markers for egfr inhibitor treatment.Info
- Publication number
- MX2010001571A MX2010001571A MX2010001571A MX2010001571A MX2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr inhibitor
- inhibitor treatment
- predictive markers
- predictive
- markers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07114292 | 2007-08-14 | ||
PCT/EP2008/006513 WO2009021674A1 (en) | 2007-08-14 | 2008-08-07 | Predictive markers for egfr inhibitor treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010001571A true MX2010001571A (en) | 2010-03-15 |
Family
ID=39884813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010001571A MX2010001571A (en) | 2007-08-14 | 2008-08-07 | Predictive markers for egfr inhibitor treatment. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2188391A1 (en) |
JP (1) | JP2010535517A (en) |
KR (1) | KR20100037637A (en) |
CN (1) | CN101778954A (en) |
AU (1) | AU2008286407A1 (en) |
BR (1) | BRPI0815415A2 (en) |
CA (1) | CA2695485A1 (en) |
MX (1) | MX2010001571A (en) |
WO (1) | WO2009021674A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2419522A4 (en) * | 2009-04-17 | 2012-10-31 | Glen Weiss | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
CN108732349A (en) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | LTA4H is as tubercle and the biomarker of early warning liver cancer in instruction liver |
CN108732351A (en) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | EPS8L2 is as tubercle and the biomarker of early warning liver cancer in instruction liver |
CN108732350A (en) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | PLA2G6 is as tubercle and the biomarker of early warning liver cancer in instruction liver |
CN110780072B (en) * | 2019-12-09 | 2021-08-06 | 四川大学华西医院 | Application of APOO autoantibody detection reagent in preparation of lung cancer screening kit |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
WO2001079556A2 (en) * | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers |
CA2515096A1 (en) * | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
KR101126560B1 (en) * | 2003-05-30 | 2012-04-05 | 도꾜 다이가꾸 | Process for predicting drug response |
ATE477495T1 (en) | 2005-03-16 | 2010-08-15 | Osi Pharm Inc | BIOLOGICAL MARKERS PREDICTIVE OF CANCER RESPONSIVENESS TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS |
AR053272A1 (en) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY |
WO2007067500A2 (en) * | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
-
2008
- 2008-08-07 BR BRPI0815415-5A2A patent/BRPI0815415A2/en not_active Application Discontinuation
- 2008-08-07 CA CA2695485A patent/CA2695485A1/en not_active Abandoned
- 2008-08-07 WO PCT/EP2008/006513 patent/WO2009021674A1/en active Application Filing
- 2008-08-07 JP JP2010520464A patent/JP2010535517A/en active Pending
- 2008-08-07 CN CN200880103326A patent/CN101778954A/en active Pending
- 2008-08-07 MX MX2010001571A patent/MX2010001571A/en not_active Application Discontinuation
- 2008-08-07 AU AU2008286407A patent/AU2008286407A1/en not_active Abandoned
- 2008-08-07 EP EP08785419A patent/EP2188391A1/en not_active Withdrawn
- 2008-08-07 KR KR1020107003315A patent/KR20100037637A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2010535517A (en) | 2010-11-25 |
CN101778954A (en) | 2010-07-14 |
BRPI0815415A2 (en) | 2015-02-03 |
WO2009021674A1 (en) | 2009-02-19 |
KR20100037637A (en) | 2010-04-09 |
AU2008286407A1 (en) | 2009-02-19 |
EP2188391A1 (en) | 2010-05-26 |
CA2695485A1 (en) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010146059A3 (en) | Biomarkers for igf-1r inhibitor therapy | |
EA201171367A1 (en) | VINYLINDASOLYL COMPOUNDS | |
WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
MX2009012625A (en) | Methods of treating, diagnosing and detecting fgf21-associated disorders. | |
MX2013002084A (en) | Biomarkers and methods of treatment. | |
ZA200702973B (en) | Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer | |
EA201270553A1 (en) | BLUTON TYROSINKINASE INHIBITORS | |
HK1145342A1 (en) | Prognosis prediction for melanoma cancer | |
WO2008008430A3 (en) | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases | |
JO2788B1 (en) | Amidophenoxyindazoles useful as inhibitors of c-met | |
EA200971068A1 (en) | TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS | |
WO2009092108A3 (en) | Biomarkers for the diagnosis and treatment of pancreatic cancer | |
MX2010001571A (en) | Predictive markers for egfr inhibitor treatment. | |
WO2008054598A3 (en) | Panel of biomarkers for prediction of fti efficacy | |
WO2010015538A3 (en) | Predictive marker for egfr inhibitor treatment | |
MX343803B (en) | Ipp complex as marker for erlotinib treatment. | |
EA200971067A1 (en) | TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS | |
EP2099458A4 (en) | Compounds and methods for enzyme-mediated tumor imaging and therapy | |
MX2010001577A (en) | Predictive marker for egfr inhibitor treatment. | |
MX2010001573A (en) | Predictive marker for egfr inhibitor treatment. | |
MX2010001582A (en) | Predictive markers for egfr inhibitors treatment. | |
MX2010001583A (en) | Predictive marker for egfr inhibitor treatment. | |
MX2010001578A (en) | Egfr inhibitor treatment marker. | |
MX2010001570A (en) | Predictive marker for egfr inhibitor treatment. | |
TN2009000448A1 (en) | Use of hdac inhibitors for the treatment of bone destruction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |